Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Status:
Unknown status
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
Study chemotherapy will consist of four treatments with Velcade (days 1, 4, 15, and 18) and
two treatments with Eloxatin(days 4 and 18). Patients will be undergo standard of care blood
work and Quality of Life (QOL) questionnaires at each visit and will be have repeat CT scans
performed to assess tumor response every 2 cycles (8 weeks). Each patient will be allowed to
receive a maximum of 6 cycles of therapy. Following discontinuation of treatment due to
disease progression or completion of therapy, patient's will be followed for survival, QOL
assessments, and tumor assessments every 3 months (or as clinically indicated) for the first
year and every 3 months thereafter for a maximum of 5 years.